MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo.

AUTHOR(S):
Horie, Takahiro; Ono, Koh; Horiguchi, Masahito; Nishi, Hitoo; Nakamura, Tomoyuki; Nagao, Kazuya; Kinoshita, Minako; ... Yokode, Masayuki; Kimura, Takeshi; Kita, Toru

CITATION:

ISSUE DATE:
2010-10-05

URL:
http://hdl.handle.net/2433/131809

RIGHT:
©2010 by the National Academy of Sciences; この論文は出版社版であるません。引用の際には出版社版をご確認ご利用ください。; This is not the published version. Please cite only the published version.
MicroRNA-33 encoded by an intron of Srebp2 regulates HDL in vivo

Takahiro Horie1,6, Koh Ono1, Masahito Horiguchi1, Hitoo Nishi1, Tomoyuki Nakamura2, Kazuya Nagao1, Minako Kinoshita1, Yasuhide Kuwabara1, Hiroyuki Marusawa3, Yoshitaka Iwanaga4, Koji Hasegawa5, Masayuki Yokode6, Takeshi Kimura1, and Toru Kita7

1Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, 606-8507, Japan
2Department of Pharmacology, Kansai Medical University, Moriguchi, Osaka, 570-8506, Japan
3Department of Gastrointestinal Medicine, Graduate School of Medicine Kyoto University, Kyoto, 606-8507, Japan
4Division of Cardiology, Department of Internal Medicine, Kinki University School of Medicine, Osaka, 589-8511, Japan
5Division of Translational Research, Clinical Research Institute, Kyoto Medical Center, Kyoto, 612-8555, Japan
6Department of Clinical Innovative Medicine, Translational Research Center, Kyoto University Graduate School of Medicine, Kyoto, 606-8507, Japan
7Department of Cardiovascular Medicine, Kobe City General Hospital, Kobe, 650-0046, Japan

Address for correspondence:

Koh Ono, MD, PhD,
Department of Cardiovascular Medicine, Graduate School of Medicine
Kyoto University, Kyoto, 54 Shogoinkawahara-cho, Sakyoku, Kyoto, 606-8507, Japan
Tel: +81-75-751-3190, Fax: +81-75-751-3203, E-mail: kohono@kuhp.kyoto-u.ac.jp
(5,039 Words, 5 Figures, 1 Table)

Nonstandard abbreviations used: ABCA1, ATP-bindng cassette transporter A1; SREBP-2, sterol regulatory element-binding protein 2; miR, microRNA; apoA, apolipoprotein A

Conflict of interest: The authors have declared that no conflict of interest exists.
Abstract

Sterol regulatory element-binding protein 2 (SREBP-2) transcription factor has been identified as a key protein in cholesterol metabolism through the transactivation of the LDL receptor and cholesterol biosynthesis genes. Here, we generated mice lacking microRNA (miR) -33, encoded by an intron of the Srebp2 gene, and showed that miR-33 repressed the expression of ATP-binding cassette transporter A1 (ABCA1) protein, a key regulator of HDL synthesis by mediating cholesterol efflux from cells to apolipoprotein A (apoA)-I. In fact, peritoneal macrophages derived from miR-33-deficient mice showed a marked increase in ABCA1 levels and higher apoA-I-dependent cholesterol efflux than those from wild-type mice. ABCA1 protein levels in liver were also higher in miR-33-deficient mice than in wild-type mice. Moreover, miR-33-deficient mice had significantly higher serum HDL cholesterol levels than wild-type mice. These data establish a critical role for miR-33 in the regulation of ABCA1 expression and HDL biogenesis in vivo.

Key Words: ABCA1, SREBP-2, HDL, macrophage, microRNA
**Introduction**

ATP-binding cassette transporter A1 (ABCA1), a 254-kDa cytoplasmic membrane protein, is a pivotal regulator of lipid efflux from cells to apolipoproteins (1). ABCA1 mediates the rate-controlling step in HDL particle formation and plays an important role in reverse cholesterol transfer (2, 3). Mutations in the *ABCA1* gene cause Tangier disease, which is characterized by the near absence of plasma HDL cholesterol associated with storage of cholesterol esters in reticuloendothelial tissues (4-7). *Abca1* mRNA and protein are very unstable with a half life of 1-2 h in murine macrophages (8), which indicates that new transcription and translation are major factors in assuring constant and inducible ABCA1 expression.

SREBPs, including SREBP-1a, -1c, and -2, modulate the transcription of a number of genes involved in the synthesis and receptor-mediated uptake of cholesterol and fatty acids (9-11). In sterol-depleted cells, SREBPs are cleaved by proteases in the Golgi, releasing the N-termini, which translocate into the nucleus and bind to SREs in the enhancers of multiple genes encoding enzymes and proteins involved in cholesterol biosynthesis and lipid uptake (11-13). Results to date support the notion that SREBP-1 primarily activates the fatty acid triglyceride and phospholipid pathways, whereas SREBP-2 is the prominent isoform for cholesterol synthesis and uptake (9, 10, 12).

MicroRNAs (miRs) are small, non-protein-coding RNAs that base pair with specific mRNAs and inhibit translation or promote mRNA degradation. Recent reports have indicated that miR-33 controls cholesterol homeostasis based on knockdown experiments using antisense technology (14-16). Antisense inhibition of miRNA function has been an important tool for elucidating miRNA biology. However, in order
to determine the potential developmental function of specific miRNAs and perform longer term studies, it is necessary to generate mice lacking each miRNA. We generated miR-33-deficient mice, which were born at the expected Mendelian ratio, and show here that miR-33, encoded by an intron16 of the Srebp2 gene, repressed the ABCA1 protein, which resulted in a reduction in HDL concentration.
**Results**

*miR-33 is encoded by intron16 of the human, mouse, cow, and chicken SREBP2 genes and targets ABCA1.* miR-33 is encoded by intron16 of the human, mouse, cow, chicken *SREBP2* genes. The sequence of miR-33 is identical and the stem-loop pre-miRNA is highly conserved in mammals (Fig. 1A). We searched for potential target genes of miR-33 in a public database (TargetScan http://www.targetscan.org/), and found that three putative miR-33 binding sites existed in the 3’-untranslated region (UTR) of the *ABCA1* mRNA, and that this region was evolutionarily conserved (Fig. 1A). To test whether the putative miR-33 target sequence in the *Abca1* 3’-UTR could mediate translational repression, we inserted the 3’-UTR of the *Abca1* transcript into a luciferase expression plasmid (luc-*Abca1* 3’-UTR), which we transfected into HEK 293T cells. CMV-driven miR-33 resulted in a decrease in luciferase activity compared with miR-146a or control vector (miR-control). Mutation in the potential binding site in the 3’-UTR abolished the effect of miR-33 (Fig.1B). Next, we transduced miR-33 into a monocytic cell line, THP-1, and a human primary hepatocyte cell line, HuS-E/2 (17), using lentivirus. The transfection efficiency of the lentivirus was always over 90% (Figure S1A and B). Overexpression of miR-33 resulted in a decrease in ABCA1 protein expression compared with the control vector in both cell lines (Fig. 1C). Because ABCA1 mediates cholesterol efflux from macrophages to lipid-free apoA-I (3), we further examined cholesterol efflux from THP-1-derived macrophages, which were differentiated from THP-1 by stimulation with phorbol 12-myristate 13 acetate (PMA) (100 nM) for 3 days. As shown in Fig.1D, apoA-I-mediated cholesterol efflux was significantly reduced in miR-33 transduced macrophages compared with miR-control transduced cells.
miR-33 is expressed with Srebp2. We next confirmed that intronic miR-33, expressed synchronously with Srebp2, is spliced to target ABCA1. We amplified genomic DNA and cDNA fragments of the mouse Srebp2 gene that cover the 5’ end of exon 16 and 3’ end of exon 17, and cloned them into a pcDNA3.1 vector, to make mini-genes that contain exon 16-intron 16-exon 17 and exon 16-exon 17 (Fig. 2A). As shown by RT-PCR, intron 16 was spliced out of the transcript of exon 16-intron 16-exon 17 in HEK 293T cells (Fig. 2B). This Srebp2 exon 16-intron 16-exon 17 mini-gene significantly suppressed luciferase activity in 293T cells transduced with a luc-Abca1 3’-UTR construct compared with the Srebp2 exon 16-exon 17 mini-gene and pcDNA3.1 empty vector (Fig. 2C). Transfection of the Srebp2 exon 16-intron 16-exon 17 mini-gene also resulted in a decrease in ABCA1 protein levels compared with the Srebp2 exon 16-exon 17 mini-gene and pcDNA3.1 empty vector in THP-1 cells (Fig. 2D). These experiments suggested that intronic miR-33 is typically and coordinately expressed with its host gene, as reported for other intronic miRNAs (18, 19).

Sterol depletion activated SREBP2 and increased miR-33 expression. To study the relevance of the miR-33/SREBP/ABCA1 cholesterol regulatory circuit, we cultured THP-1 cells under sterol-depleted conditions by the removal of serum from the culture media (SFM) or in the presence of statin. Under these conditions, THP-1 cells had normal morphology and no cell death was detected. As shown in Fig. 3A, SFM decreased ABCA1 protein levels in THP-1 cells in a time-dependent manner. LDL-receptor and SREBP2 mRNA expression levels increased in a time-dependent manner after serum depletion (Fig. 3B and C). Expression of miR-33 paralleled SREBP2 expression (Fig. 3D). The same experiment was conducted in cells treated with simvastatin. Simvastatin reduced the expression of ABCA1 in a dose- and
time-dependent manner (Fig. S2A and B). The expression levels of \textit{LDL-receptor}, \textit{SREBP2}, and miR-33 increased in time-dependent manners as in SFM (Fig. S2C-E). We further suppressed endogenous miR-33 in THP-1-derived macrophages by the transduction of a ‘decoy’ gene, which contained 9-tandem repeats of antisense sequences against miR-33 downstream of the luciferase gene (Fig. S3A). Overexpression of miR-33 along with this decoy gene significantly suppressed luciferase activity (Fig. S3B). The suppression of ABCA1 protein levels in response to sterol depletion was reversed by the miR-33 decoy gene (Fig. S3C), which was consistent with the notion that miR-33 mediates cholesterol-regulated post-transcriptional control of ABCA1 levels.

\textit{Generation of miR-33-deficient mice.} We deleted the region that encodes the complete pre-miRNA sequence of miR-33 by introducing loxP sites for Cre-mediated recombination into intron 16 of the mouse \textit{Srebp2} gene (Fig. 4A, B, and C). Because disruption of the \textit{Srebp2} gene causes embryonic lethality (20), it was important that the miR-33 targeting strategy did not alter \textit{Srebp2} transcription or splicing. Deletion of miR-33 did not alter the expression of SREBP-2 protein (Fig. 4D) or interfere with \textit{Srebp2} mRNA splicing and expression (Fig. 4E and Fig. S4) in miR-33-deficient mice. \textit{Srebp2} mRNA splicing and expression were not altered even at later time points (Fig. S5). Relative expression levels of miR-33 and \textit{Srebp2} are shown in Fig. S6A. miR-33 appears to be coexpressed with the \textit{Srebp2} host gene as seen in THP-1 cells (Fig. 3). Loss of miR-33 expression in these mice was confirmed in the liver (Fig. 4F) and in other organs (Fig. S6B and C) by real-time PCR. Mice homozygous for the miR-33 deletion were born at the expected Mendelian ratio, were viable, fertile, and did not display obvious abnormalities in size, shape, or structure up to 16 weeks of age.
miR-33 deficiency enhances cholesterol efflux in macrophages. To investigate the role of miR-33 in mice, we first compared the function of peritoneal macrophages in wild-type and miR-33-deficient mice. ABCA1 protein expression levels were considerably higher in macrophages of miR-33-deficient mice than those of wild-type mice (Fig. 5A). We measured apoA-I-mediated cholesterol efflux from peritoneal macrophages and found that macrophages in miR-33-deficient mice had higher apoA-I-mediated cholesterol efflux than wild-type mice (Fig. 5B).

miR-33 deletion enhances HDL levels. Overexpression of hepatic ABCA1 raises HDL cholesterol levels (21), and liver-specific deletion of ABCA1 results in a substantial (~80%) decrease in plasma HDL cholesterol in chow-fed mice (22). Therefore, we measured ABCA1 protein expression levels in the liver. Fig. 5C and D indicate that ABCA1 protein levels were higher in miR-33-deficient mice liver than in wild-type mice liver of both genders. High-performance liquid chromatography (HPLC) with gel permeation columns was used for classifying and quantifying lipoproteins on the basis of differences of particle size (23, 24). Figure 5E and F show representative results of the HPLC elution profile of serum from wild-type (black) and miR-33-deficient mice (red) at the age of 16 weeks. HDL from miR-33-deficient mice showed a broader peak with a slight shift to the left consistent with cholesterol enrichment. Serum lipid profiles of mice at the age of 16 weeks are summarized in Table 1. miR-33-deficient mice had significantly higher total cholesterol and HDL cholesterol levels than wild-type mice, whereas triglyceride levels were unchanged. Elevation of HDL was prominent in female mice. In fact, the expression level of miR-33 showed an approximately 1.5 fold increase in the liver of wild-type female mice compared with wild-type male mice (Fig. S6D). Moreover, the increased levels of HDL were mainly composed of very large, large, and
medium HDL (mature HDL). Because Abcg1, which is required for cholesterol efflux to HDL and contributes to form mature HDL, is a potential target of miR-33 in rodents (not human) (14, 16) (Fig. S7A), we also inserted the 3’-UTR of the Abcg1 transcript into a luciferase expression plasmid (luc-Abcg1 3’-UTR). CMV-driven miR-33 resulted in a decrease in luciferase activity compared with miR-146a or control vector (miR-control) in HEK 293T cells. Mutation in the potential binding site in the 3’-UTR abolished the effect of miR-33 (Fig.S7B). We further measured the protein levels of ABCG1 in liver. However, the levels were the same in wild-type and miR-33-deficient mice of both genders (Fig. S7C and D).
Discussion

Recent studies have shown that miR-33 helps to regulate the homeostasis of HDL cholesterol, suggesting that it might be a possible target for the treatment of cardiovascular and metabolic disorders (14-16), which reported similar or complementary findings. Expression of miR-33 was found in various cells and tissues, including macrophages, hepatic cells, endothelial cells, brain, liver, colon, small intestine and skeletal muscle. The predominant target identified for miR-33 was the gene encoding \textit{ABCA1}. It was suggested that miR-33 antisense approaches resulted in augmented HDL-cholesterol levels in mice. One report indicated that three injections of locked nucleic acid (LNA) antisense over 5 days elevated plasma HDL-cholesterol levels by about 35% with only modest effects of miR-33a LNA-antimiR on hepatic \textit{ABCA1} mRNA/protein levels as compared with control mice fed on a high fat diet (15). Another report showed that overexpression of antisense miR-33 using lenti-virus showed a 50% increase in hepatic \textit{ABCA1} protein levels and a concomitant 25% increase in plasma HDL levels after 6 days (14). Marquart et al. indicated that injection of an anti-miR-33 oligonucleotide resulted in a substantial increase in \textit{ABCA1} expression and HDL levels (16).

Antisense inhibition of miRNA function has been an important tool for elucidating miRNA biology. However, in order to determine the potential developmental functions and perform longer term studies, it is necessary to completely ablate the miRNA under investigation. We generated mice lacking miR-33, encoded by an intron of the \textit{Srebp2} gene. The major findings obtained by the analysis of miR-33-deficient mice were that 1) mice homozygous for the miR-33-deletion were born at the expected Mendelian ratio, were viable, fertile, and did not display obvious
abnormalities in size, shape, or structure up to 16 weeks of age; 2) Complete loss of miR-33 enhanced liver ABCA1 protein levels remarkably, and serum HDL levels were elevated by about 22% in male and 39% in female mice, probably because the expression level of miR-33 was 1.5-fold higher in the liver of female mice compared with male mice; 3) the increased levels of HDL were mainly composed of very large, large, and medium HDL (mature HDL), which was consistent with the results obtained in hABCA1 transgenic mice (25); and 4) although the in vitro experiment suggested that Abcg1 is also a potential target of miR-33, the depletion of miR-33 did not alter the expression levels of ABCG1 protein in liver. Rayner et al. could also not see the difference in hepatic ABCG1 protein expression levels between mice 6 days after injection with control and anti-miR-33 lentivirus (14). Thus, our results unambiguously indicated that miR-33 regulates plasma HDL levels through the repression of ABCA1 in vivo.

Gene regulation via miRNAs is a strongly conserved mechanism found in nearly all multicellular organisms, including animals and plants (26). Mammalian genomes encode more than 500 known miRNA genes. Approximately 50% are expressed from non-protein coding transcripts, whereas the rest are located mostly in the introns of genes (27). Intronic miRNAs are generally transcribed coincidentally with their host genes (28). In the present study we showed the presence of miR-33 within the intronic sequence in the Srebp2 gene and examined whether miR-33 is expressed with its host gene. In vitro studies demonstrated that Srebp2 intron 16 suppressed ABCA1 protein expression in the same way as miR-33. The co-regulation of a miRNA with its host gene typically exhibits one of two main functions; 1) an antagonistic effect by miRNA mediated knock-down of genes with perturbing effects on a pathway or a biological
process activated by the host gene, or 2) a synergistic effect by miRNA-mediated fine tuning of a target gene generating a positive effect on the host gene. In this case, miR-33 has a synergistic effect on ABCA1 via its host gene Srebp2 because SREBP-2 is known to suppress the transcription of Abca1 in vascular endothelial cells (29). SREBPs are activated in sterol-depleted conditions and serve as transcription factors for lipid/cholesterol synthesis, uptake, storage, and efflux (11-13, 29). In peripheral cells intracellular cholesterol homeostasis is precisely regulated and depends on the balance between cholesterol synthesis, degradation, cholesterol ester formation, influx, and efflux (30, 31). Because SREBPs are activated by HMG-CoA reductase inhibitor accompanied by an increased in the expression of miR-33, ABCA1 expression and cholesterol efflux are presumably suppressed by miR-33 in these conditions.

In humans, SREBP1 and SREBP2 encode miR-33b and miR-33a, respectively(15). It is well known that hypertriglyceremia in metabolic syndrome is caused by the insulin-induced increase in SREBP1c mRNA and protein levels(32, 33). Low HDL often accompanies this situation and it is possible that the reduction in HDL is caused by a decrease in ABCA1, because of the increased production of miR-33b from the insulin-induced induction of SREBP1c. Although it is impossible to prove this in animal models that lack miR-33b, antagonizing miR-33 could be a promising way to raise HDL levels when the transcription of both SREBPs is upregulated. Thus, our study suggests that a combination of silencing of endogenous miR-33 and statins may be a useful therapeutic strategy for raising HDL and lowering LDL levels especially for metabolic syndrome subjects.
Materials and Methods

Cells and plasmids

Immortalized human primary hepatocyte HuS-E/2 cells were described previously (17). Other cells and plasmids used in this experiment are summarized in Supplemental Materials and Methods.

Generation of miR-33 deficient mice

A targeting vector was constructed by modifying bacterial artificial chromosome RP24-291F2 (Invitrogen) using defective prophage λ-Red recombination system (34, 35) As a selection marker, a neomycin resistance cassette flanked by loxP sites (loxP-PGK-gb2-neo-loxP cassette; Gene Bridges, Germany) was inserted at the pre-miR-33 site. The targeting vector was electroporated into C57BL/6 mouse ES cells (DS Pharma Biomedical) using a Nucleofector system (Lonza). Positive clones were selected by incubating cells with 200 mM geneticin (Invitrogen) for 5 days, and homologous recombination was confirmed by Southern blotting. Successfully recombined ES cells were injected into blastocysts from ICR strain mice supplied by Unitech Inc. (Japan), and chimeric mice were bred with C57BL/6 mice to generate F1 mice. The genotype of F1 mice was confirmed by Southern blotting. The neomycin resistance cassette was removed in the mouse germ line by breeding heterozygous mice with Ayu-1 Cre knockin mice, which express Cre recombinase in multiple tissues, including the germ line (36). Descendant miR-33 heterozygous mice without the Ayu-1 Cre allele were crossed with each other to generate miR-33-deficient mice. All experiments were carried out in C57BL/6 background mice and wild-type littermates were used as a control. Primer sequences for the probe (865 bp) for Southern blotting
and genotyping (WT: 385 bp, KO: 491 bp) are indicated in the Supplemental Materials and Methods.

**Lentivirus production and DNA transduction**

We produced lentiviral stocks in 293FT cells in accordance with the manufacturer’s protocol (Invitrogen). Cells were used for analyses two days after transduction.

**Luciferase assay**

To create wild-type or mutant 3’UTR luciferase reporter constructs, a fragment of the 3’UTR of the *Abca1* and *Abcg1* genes (Supplemental Materials and Methods) was subcloned downstream of a CMV-driven firefly luciferase cassette in a pMIR-REPORT vector (Ambion). Luciferase activities were measured as described previously (37).

**Cellular cholesterol efflux from macrophages**

Cellular cholesterol efflux via apoA-I was determined as described previously (38).

**Serum lipid profiling**

Lipoproteins were analyzed by high-performance liquid chromatography at Skylight Biotech (Akita, Japan), in accordance with the procedure described by Usui et al. (24).

**Statistics**

Data are presented as means ± S.E. Statistical comparisons were performed using unpaired two-tailed Student’s *t*-tests or one-way analysis of variance with Bonferonni.
post hoc test where appropriate, with a probability value of <0.05 taken to indicate significance.
Acknowledgments

We thank N. Sowa, for providing excellent technical assistance; Neal G. Copeland (Institute of Molecular and Cell Biology, Singapore) for the defective prophage $\lambda$-Red recombination system; Junji Takeda (Osaka University, Osaka, Japan) and Kosuke Yusa (Osaka University, Osaka, Japan) for the plasmid used for the construction of the targeting vector; Ken-ichi Yamamura (Kumamoto University, Kumamoto, Japan) and Kimi Araki (Kumamoto University) for Ayu-1 Cre expressing mice; Makoto Hijikata (Institute for Virus Research, Kyoto University, Kyoto, Japan) for HuS-E/2. This work was supported in part by grants from the Global COE program “Center for Frontier Medicine” and from the Japan Society for the Promotion of Science, and the Ministry of Education, Culture, Sports, Science, and Technology of Japan (to T. Kimura, T. Kita, K.H., T.H., and K.O.).
References

human intronic microRNAs with their host genes PLoS One 4: e4421.
775-783.
in livers of mice homozygous for a targeted disruption of the SREBP-1 gene J
Clin Invest 100: 2115-2124.
intrahepatic cholesterol and plasma HDL cholesterol concentrations J Lipid Res
44: 296-302.
profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I J
visceral obesity by component analysis of cholesterol profile in
high-performance liquid chromatography Arterioscler Thromb Vasc Biol 25:
578-584.
method for simultaneous quantification of cholesterol and triglycerides in
25. Vaisman B L, et al. (2001) ABCA1 overexpression leads to
hyperalphalipoproteinemia and increased biliary cholesterol excretion in
development Science 301: 336-338.
down-regulates ATP-binding cassette transporter A1 in vascular endothelial
cells: a novel role of SREBP in regulating cholesterol metabolism J Biol Chem
279: 48801-48807.
and familial high-density lipoprotein deficiency Curr Opin Lipidol 11: 117-122.
38: 1503-1521.
X receptor in insulin-mediated activation of Srebp-1c transcription and
stimulation of fatty acid synthesis in liver Proc Natl Acad Sci U S A 101:
11245-11250.
interaction with cross-linking enzyme lysyl oxidase Proc Natl Acad Sci U S A
106: 19029-19034.


Figure legends

Fig. 1. ABCA1 is a target of miR-33.
A. Schema and sequence alignment of SREBP2, miR-33, and ABCA1 3’UTR. miR-33 is located in intron16 of SREBP2. There are 3 potential conserved miR-33 binding sites in the ABCA1 3’UTR.
B. 293T cells were transfected with wild-type or mutant Abca1 3’UTR luciferase constructs, along with expression plasmids for miR-control (negative control), miR-33, and miR-146a. Values are the means ± S.E. of 4 independent experiments. *p<0.01 compared with other columns.
C. Western analysis of ABCA1 in THP-1-derived macrophages and HuS-E/2 (human primary hepatocytes) transfected with miR-control and miR-33, using a lentivirus vector.
D. Cholesterol efflux was measured in the presence or absence of apoA-I (15 µg/ml) for 24 hours in THP-1-derived macrophages transfected with miR-control and miR-33. Values are the means ± S.E. of 3 independent experiments. *p<0.01.

Fig. 2. Analysis using the Srebp2 mini-gene.
A. Schema of the Srebp2 mini-gene used in this report. Arrows indicates RT-primers.
B. RT-PCR analysis of 293T cells transfected with the Srebp2 mini-gene. Note that there is no band around 2000 bp, indicating that intron 16 was correctly spliced.
C. 293T cells were transfected with the wild-type Abca1 3’UTR luciferase construct, along with the expression plasmids. Values are the means ± S.E. of 4 independent experiments. *p<0.05 compared with empty vector (pcDNA3.1) or the Srebp2 mini-gene (exon 16-exon 17).
D. Western analysis of ABCA1 in THP-1 macrophages transfected with the Srebp2 mini-gene using lentivirus vectors. GAPDH was used as a loading control.

Fig. 3. The effect of serum starvation in THP-1 macrophages.
A. Western analysis of ABCA1 protein levels under serum starvation conditions for the indicated time periods in THP-1 macrophages. GAPDH was used as a loading control.
B. Quantitative real-time PCR analysis of LDL receptor expression levels under serum starvation conditions for the indicated time periods in THP-1 macrophages. Values are the means ± S.E. of 6 independent experiments with normalization using GAPDH expression. *p<0.05 compared with 10% FBS.
C. Quantitative real-time PCR analysis of SREBP2 expression levels under serum starvation conditions for the indicated time periods in THP-1 macrophages. Values are the means ± S.E. of 6 independent experiments with normalization using GAPDH expression. *p<0.05 compared with 10% FBS.
D. Quantitative real-time PCR analysis of miR-33 under serum starvation conditions for the indicated time periods in THP-1 macrophages. Values are the means ± S.E. of 6 independent experiments with normalization using U6 snRNA. *p<0.05 compared with 10% FBS.

Fig. 4. Generation of miR-33-deficient mice.
A. Strategy to generate miR-33-deficient mice by homologous recombination. The
pre-miR-33 sequence was replaced with a neomycin resistance cassette (pgk-gb2-Neo) flanked by loxP sites. The neomycin resistance cassette was removed in the mouse germ line by breeding heterozygous mice with Ayu-1 Cre mice, which express Cre recombinase in multiple tissues, including the germ line.

B. Southern blotting of mice tail genome.
C. PCR analysis of mice tail genome.
D. Western analysis of SREBP-2 in the liver of 8-week-old male mice (Precursor: 126 kDa, Mature: 55 kDa). GAPDH was used as a loading control.
E. RT-PCR analysis of Srebp2 in the liver of 8-week-old male mice. The sense primer was designed in exon 16 of Srebp2 and the antisense primer was designed in exon 17 of Srebp2. Gapdh was used as a control.
F. Quantitative real-time PCR analysis of miR-33 in the liver of 8-week-old male mice, using a Taqman microRNA assay (N.D.: not determined).

Fig. 5. ABCA1 expression of peritoneal macrophages and the liver in wild-type and miR-33-deficient mice.
A. Western analysis of ABCA1 in peritoneal macrophages. Thioglycolate-elicited peritoneal macrophages were isolated from 8-week-old wild-type and miR-33-deficient mice. GAPDH was used as a loading control.
B. Cholesterol efflux from peritoneal macrophages was measured in the presence or absence of apoA-I (15 μg/ml) for 6 hours. Values are the means ± S.E. of 6 independent experiments. *p<0.01.
C. Western analysis of hepatic ABCA1 and SREBP-2 in 16-week-old male mice. GAPDH was used as a loading control.
D. Western analysis of hepatic ABCA1 and SREBP-2 in 16-week-old female mice. GAPDH was used as a loading control.
E. Representative HPLC analysis of serum cholesterol from male wild-type and miR-33-deficient mice.
F. Representative HPLC analysis of serum cholesterol from female wild-type and miR-33-deficient mice.
**Figure 1**

**A**

- **SREBP2** (Human)
  - Exons 1-16
  - miR-33
  - Exons 17-24

<table>
<thead>
<tr>
<th>miRNA</th>
<th>Seed Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>hsa-miR-33</td>
<td>CUGUGGUCAUUUGUAGUUGCAUUGCAUGUUCUGUGGUACUAGCGAUGUUCAGUUCACAG</td>
</tr>
<tr>
<td>mmu-miR-33</td>
<td>CUGUGGUCAUUUGUAGUUGCAUUGCAUGUUCUGUGGUACUAGCGAUGUUCACAGG</td>
</tr>
<tr>
<td>bta-miR-33</td>
<td>CUGUGGUCAUUUGUAGUUGCAUUGCAUGUUCUGUGGUACUAGCGAUGUUCACAG</td>
</tr>
<tr>
<td>gga-miR-33</td>
<td>CUGUGGUCAUUUGUAGUUGCAUUGCAUGUUCUGUGGUACUAGCGAUGUUCACAG</td>
</tr>
</tbody>
</table>

**ABCA1 3'UTR**

miR-33 binding site

<table>
<thead>
<tr>
<th>Species</th>
<th>Seed Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hsa (Human)</td>
<td>AACUGGAAUCUGAUCUGAUCUAAUCUAUGCAAUUGCAUUGAAAC</td>
</tr>
<tr>
<td>Mmu (Mouse)</td>
<td>AACUGGAAUCUGAUCUGAUCUAAUCUAUGCAAUUGCAUGAAGAAC</td>
</tr>
<tr>
<td>Bta (Cow)</td>
<td>AACUGGAAUCUGAUCUGAUCUAAUCUAUGCAAUUGCAUGAAGAAC</td>
</tr>
<tr>
<td>Gga (Chicken)</td>
<td>AACUGGAAUCUGAUCUGAUCUAAUCUAUGCAAUUGCAUGAAGAAC</td>
</tr>
</tbody>
</table>

**B**

- **Abca1 3'UTR**
  - Relative luciferase activity
  - WT
  - Mutant

<table>
<thead>
<tr>
<th>miRNA</th>
<th>Relative luciferase activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-control</td>
<td>0.75 ± 0.05</td>
</tr>
<tr>
<td>miR-33</td>
<td>0.25 ± 0.05</td>
</tr>
<tr>
<td>miR-33</td>
<td>0.25 ± 0.05</td>
</tr>
<tr>
<td>miR-control</td>
<td>0.75 ± 0.05</td>
</tr>
</tbody>
</table>

**C**

- **THP-1 macrophage**
- **Hus-E/2** (Immortalized human primary hepatocyte)

- **GAPDH**
- **ABCA1**

**D**

- **Cholesterol efflux (%)**
- **ApoA-I**

<table>
<thead>
<tr>
<th>ApoA-I</th>
<th>miR-control</th>
<th>miR-33</th>
</tr>
</thead>
<tbody>
<tr>
<td>-</td>
<td>5</td>
<td>25</td>
</tr>
<tr>
<td>-</td>
<td>5</td>
<td>25</td>
</tr>
<tr>
<td>+</td>
<td>0</td>
<td>20</td>
</tr>
<tr>
<td>+</td>
<td>0</td>
<td>20</td>
</tr>
</tbody>
</table>
**Figure 2**

A. Diagram showing the constructs for luciferase activity:
- Empty (pcDNA3.1)
- Srebp2 mini-gene (exon 16-exon 17)
- Srebp2 mini-gene (exon 16-intron 16-exon 17)

B. Gel electrophoresis showing RT-PCR results:
- Srebp2 RT-PCR
- Gapdh RT-PCR

C. Bar graph showing relative luciferase activity:
- Empty (pcDNA3.1)
- Srebp2 mini-gene (exon 16-exon 17)
- Srebp2 mini-gene (exon 16-intron 16-exon 17)

D. Western blot analysis for ABCA1 and GAPDH
Figure 3

(A) Western blot analysis showing ABCA1 and β-actin expression with 10% FBS, SFM 6 h, SFM 24 h, and SFM 48 h treatments.

(B) Graph showing LDL-receptor/GAPDH expression levels with significant differences indicated by *.

(C) Graph showing SREBP2/GAPDH expression levels with significant differences indicated by *.

(D) Graph showing miR-33/U6 expression levels with significant differences indicated by *.

A Self-archived copy in Kyoto University Research Information Repository
https://repository.kulib.kyoto-u.ac.jp
Figure 4

(A) Modification vector

(B) Genotyping by PCR

(C) Targeted allele

(D) Western blot analysis

(E) Gene expression analysis

(F) miR-33 expression

Figure 4
### Figure 5

**Panel A**
- Western blot analysis of ABCA1 and GAPDH in various genotypes (+/+ and -/-).

**Panel B**
- Cholesterol efflux (%)
- Bar graph showing the cholesterol efflux in the absence (+) and presence (-) of ApoA-I.

**Panel C**
- Western blot analysis of ABCA1, SREBP-2 (Precursor), SREBP-2 (Mature), and GAPDH in +/+ and -/- genotypes.

**Panel D**
- Western blot analysis of ABCA1, SREBP-2 (Precursor), SREBP-2 (Mature), and GAPDH in +/+ and -/- genotypes.

**Panel E**
- Elution time vs. Cholesterol Absorbance Units (mV) for Male.
- Cholesterol elution profile for +/+ and -/- genotypes.

**Panel F**
- Elution time vs. Cholesterol Absorbance Units (mV) for Female.
- Cholesterol elution profile for +/+ and -/- genotypes.

---

**Figure 5**
## Table 1

<table>
<thead>
<tr>
<th>Lipoprotein</th>
<th>Males (+/+) n=6</th>
<th>(−/−) n=5</th>
<th>Females (+/+) n=6</th>
<th>(−/−) n=5</th>
</tr>
</thead>
<tbody>
<tr>
<td>TC (mg/dl)</td>
<td>73.70 ± 3.39</td>
<td>85.90 ± 4.11  *</td>
<td>58.56 ± 3.37</td>
<td>78.19 ± 4.41  **</td>
</tr>
<tr>
<td>CM (1-2) &gt;80 nm</td>
<td>0.13 ± 0.03</td>
<td>0.21 ± 0.07</td>
<td>0.09 ± 0.02</td>
<td>0.12 ± 0.03</td>
</tr>
<tr>
<td>VLDL (3-7) 30-80 nm</td>
<td>4.89 ± 0.75</td>
<td>4.04 ± 0.75</td>
<td>3.82 ± 0.37</td>
<td>3.49 ± 0.24</td>
</tr>
<tr>
<td>LDL (8-13) 16-30 nm</td>
<td>13.25 ± 0.48</td>
<td>13.31 ± 0.90</td>
<td>13.78 ± 0.53</td>
<td>17.89 ± 1.57  *</td>
</tr>
<tr>
<td>Large LDL (8)</td>
<td>2.16 ± 0.13</td>
<td>2.31 ± 0.29</td>
<td>2.76 ± 0.23</td>
<td>3.10 ± 0.32</td>
</tr>
<tr>
<td>Medium LDL (9)</td>
<td>4.32 ± 0.15</td>
<td>4.05 ± 0.22</td>
<td>4.90 ± 0.23</td>
<td>5.95 ± 0.68</td>
</tr>
<tr>
<td>Small LDL (10)</td>
<td>3.27 ± 0.22</td>
<td>2.86 ± 0.16</td>
<td>3.12 ± 0.12</td>
<td>4.02 ± 0.40  *</td>
</tr>
<tr>
<td>Very small LDL (11-13)</td>
<td>3.51 ± 0.20</td>
<td>4.09 ± 0.51</td>
<td>2.99 ± 0.31</td>
<td>4.82 ± 0.46  *</td>
</tr>
<tr>
<td>HDL (14-20) 8-16 nm</td>
<td>55.42 ± 2.82</td>
<td>67.55 ± 4.09  *</td>
<td>40.88 ± 3.22</td>
<td>56.69 ± 3.82  *</td>
</tr>
<tr>
<td>Very large HDL (14-15)</td>
<td>3.85 ± 0.24</td>
<td>5.77 ± 0.64  *</td>
<td>3.60 ± 0.66</td>
<td>5.97 ± 0.71  *</td>
</tr>
<tr>
<td>Large HDL (16)</td>
<td>16.50 ± 0.88</td>
<td>22.15 ± 1.35  **</td>
<td>14.81 ± 1.79</td>
<td>21.04 ± 1.81  *</td>
</tr>
<tr>
<td>Medium HDL (17)</td>
<td>22.01 ± 1.18</td>
<td>25.65 ± 1.39</td>
<td>14.50 ± 0.73</td>
<td>19.57 ± 1.19  **</td>
</tr>
<tr>
<td>Small HDL (18)</td>
<td>9.24 ± 0.52</td>
<td>9.61 ± 0.63</td>
<td>5.30 ± 0.05</td>
<td>6.70 ± 0.33  **</td>
</tr>
<tr>
<td>Very small HDL (19-20)</td>
<td>4.75 ± 0.19</td>
<td>5.12 ± 0.30</td>
<td>3.24 ± 0.09</td>
<td>3.60 ± 0.42</td>
</tr>
<tr>
<td>TG (mg/dl)</td>
<td>45.87 ± 6.20</td>
<td>37.26 ± 4.90</td>
<td>20.70 ± 2.64</td>
<td>20.64 ± 1.67</td>
</tr>
</tbody>
</table>

*Values are mean ± S.E. Blood was obtained from chow-fed 16-week-old mice after fasting for 4 hours.

Serum was analysed by HPLC, as described in the Materials and Methods.

TC, total cholesterol; TG, triglyceride; CM, chylomicrons; VLDL, very low density lipoprotein; LDL, low density lipoprotein; HDL, high density lipoprotein.

*p<0.05, **p<0.01 compared with wild-type mice